A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Incomplete Freund's adjuvant; Lenalidomide; Montanide ISA-51; Sargramostim
Indications Multiple myeloma
Focus Adverse reactions

30 May 2023 Planned End Date changed from 9 Nov 2023 to 19 May 2026.
02 Mar 2023 Planned primary completion date changed from 30 Jan 2023 to 30 Apr 2023.
13 Dec 2022 Interim Results ( At data-cut off, n=7), presented at the 64th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com